📉 The Financial Deep Dive
Suraksha Diagnostic Limited has unveiled a strong Q3 and nine-month (9M) performance for FY26, underscored by significant revenue acceleration driven by strategic expansion. For the third quarter ended December 31, 2025, Total Income surged 30.3% YoY to ₹783 million, up from ₹601 million in Q3 FY25. This top-line momentum translated into EBITDA growth of 26.1% YoY to ₹237.8 million. However, the EBITDA margin compressed to 30.6% from 31.7% in the prior year's quarter, and PAT grew 21.0% YoY to ₹72.4 million with a PAT margin of 9.3% (down from 10.1% YoY).
The nine-month period ending December 31, 2025, saw Total Income increase by 21.8% YoY to ₹2,313.8 million. EBITDA rose 12.8% YoY to ₹734 million, but margins contracted to 31.7% from 34.8% in 9M FY25. PAT for the period was ₹252.4 million, a 6.0% YoY increase, with margins at 11.0% (down from 12.7% YoY).
For the full fiscal year FY25, the company reported Total Revenue of ₹2,559.4 million (+15.2% YoY), with EBITDA of ₹850.9 million (+15.6% YoY) and stable margins of 33.8%. PAT saw a substantial 34.0% YoY growth to ₹309.8 million.
📊 The Quality & Strategy
The reported margin compression is a direct consequence of the company's aggressive 'Invest for Scale' strategy. Management attributes the dip in EBITDA and PAT margins to planned pre-operative expenses for 12 new centers (6 already operational, 6 under development, with 6 more slated for Q4 FY26). Crucially, the core business, comprising centers operational for over two years, continues to deliver strong EBITDA margins of approximately 37%, validating the efficiency of its 'hub and spoke' model. The company has also strategically acquired a 63% stake in Fetomat Wellness Private Limited, a fertility and pregnancy care clinic network, and launched 'Suraksha Genomics', aiming to capture growth in high-impact areas. This approach signals a short-term margin sacrifice for long-term market dominance, particularly in the underserved Eastern Indian market.
🚩 Risks & Outlook
Specific Risks: The primary risks revolve around the execution of its ambitious expansion plans, including the successful ramp-up of new centers and the integration of acquisitions. Continued pressure on margins from ongoing pre-operative expenses is expected in the near term. Competitive intensity in the diagnostics sector also remains a factor.
The Forward View: Investors should monitor the pace at which new centers achieve operational efficiency and contribute to profitability. The success and market reception of the 'Suraksha Sutra' genomics vertical and the Fetomat acquisition will be key indicators. The company's ability to restore and potentially improve margins as new facilities mature will be critical for its long-term valuation. The projected 10-12% CAGR for the Indian diagnostics market and specific growth in Eastern India (10.5-12.5% CAGR) provide a favorable backdrop for Suraksha's expansion strategy.